treatment

A Reduced-Intensity Conditioning Regimen (Cyclophosphamide, Pentostatin, ATG) Followed by Haploidentical Hematopoietic Stem Cell Transplant for the Treatment of Patients with Refractory or Recurrent Severe Aplastic Anemia

Status
Recruiting
Study Date (Range)
-
Bone Marrow Disease(s)
Aplastic Anemia
Age Group
40 years to 75 years
The current standard treatment for aplastic anemia (AA) is immunosuppressive therapy (IST), with only temporary symptom relief and high rates of paroxysmal nocturnal hemoglobinuria, clonal hematopoiesis, and myelodysplastic syndrome. When a matched donor is available, allogeneic…

Yasmin Abaza, MD

Institution
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)

Stephen Chung, MD

Institution
UT Southwestern Medical Center
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Myelodysplastic Syndromes (MDS)
About
Stephen Chung, M.D., is an Assistant Professor in the Department of Internal Medicine and the Children’s Research Institute at UT Southwestern Medical Center. He specializes in the care of patients with the myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Dr. Chung earned his medical degree at Washington University School of Medicine in St. Louis. He completed a residency in internal medicine at Massachusetts General Hospital followed by a medical oncology fellowship at Memorial Sloan Kettering Cancer Center (MSKCC), where he remained as a faculty member of the Leukemia

Neal Young, MD

Institution
National Heart, Lung, and Blood Institute - National Institutes of Health
Physician Status
accepting new patients
Primary Disease Area of Focus
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Pediatric
About
Neal Young received a A.B. cum laude from Harvard College in 1967 and his M.D. in 1971 from the Johns Hopkins School of Medicine. He did post-graduate medical training at Massachusetts General Hospital and Barnes Hospital at Washington University in St. Louis before joining the NHLBI in 1981. He is a Master of the American College of Physicians and has accrued many academic honors. His efforts as a US Government employee were recognized with Samuel J. Heyman Service to America Medal in Science and the Environment. Dr. Young has authored over 280 original scientific and medical articles in peer

David B. Sykes, MD, PhD

Institution
Mass General Hospital
Physician Status
accepting new patients
Primary Disease Area of Focus
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
About
David completed his undergraduate training in Biochemistry at the University of Alberta in Edmonton, Canada. He entered the Medical Scientist Training Program (M.D., Ph.D.) at the University of California San Diego and carried out his Ph.D. research with Dr. Mark Kamps where he became interested in the problems that arise during white blood cell development. David did his internship and residency at the Massachusetts General Hospital as well as a year as a Chief Medical Resident in the Department of Internal Medicine. He was a Hematology and Oncology fellow in the combined Dana-Farber Cancer

Zhuoer Xie, MD, MS

Institution
Moffitt Cancer Center
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Chronic Myelomonocytic Leukaemia (CMML)
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
About
Dr. Xie is a hematologist and assistant member in the Moffitt Cancer Center Malignant Hematology Department. Dr. Xie completed her hematology/oncology fellowship training at the Mayo Clinic, Rochester, MN, Master of Science in Clinical Research and Geriatric fellowship training at the UCLA, Ronald Reagan Medical Center. She focuses on treating myeloid malignancies and precursor stages, including clonal hematopoiesis of indeterminate potential (CHIP), clonal cytopenia (CCUS), MDS, MPN, CMML, and Acute Leukemia. Her research focuses on clinical and translational science, including identifying

Tian Yi Zhang, MD, PhD

Institution
Stanford University School of Medicine
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Myelodysplastic Syndromes (MDS)
About
Dr. Zhang is a board-certified hematologist. She is also an assistant professor of hematology at Stanford University School of Medicine. In addition to her medical degree, she holds a PhD in cellular and molecular immunology. In her clinical practice, she treats patients with all forms of hematological malignancies, offering specialized expertise in acute myeloid leukemia, including therapy-resistant cases. For each patient, she develops a personalized care plan encompassing novel treatment options. Her research activities include conducting early phase clinical trials, investigator initiated
Subscribe to treatment

Website Feedback

Please use this feedback form to report website issues only. For other issues concerning patients and families, please email help@aamds.org or use the Patient and Family Helpline here.